Entry into a Material Definitive Agreement. On July 28, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) executed a lease agreement (the “Office Lease”) with Bradford Street, L.L.C. (“Bradford Street”) for approximately 4,067 square feet of office space located at 23 Bradford Street, Concord, Massachusetts (the “Premises”). The Office Lease commences on September 1, 2026 and the term with respect to the Premises shall be for a period ending on September 30, 2029. The Company inte…

Director, Chair of the Audit Committee — Darlene Deptula-Hicks: Ms. Deptula-Hicks was appointed as a director and Chair of the Audit Committee.

Director — Martin J. Joyce: Mr. Joyce decided not to stand for re-election at the upcoming annual meeting.

Other Events. As previously disclosed, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) entered into that certain Loan and Security Agreement, dated as of March 25, 2019, by and among the Company, Helio Vision, LLC, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”) and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the Lenders (as amended from time to time, the “Hercules…

of this Current Report on Form 8-K, on March 17, 2026, Aldeyra announced receipt of the 2026 Complete Response Letter. The 2026 Complete Response Letter stated that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate effica…

Chief Development Officer — Stephen G. Machatha, Ph.D.: Dr. Stephen G. Machatha voluntarily resigned from his position as Chief Development Officer to pursue other professional opportunities.

of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Various statements to be made during the conference call and included in the Press Rel…

Regulation FD Disclosure. On November 13, 2025, Aldeyra Therapeutics, Inc. (“Aldeyra”) intends to make a slide presentation at its previously announced 2025 Research & Development Webcast (the “2025 Research and Development Webcast”). A copy of Aldeyra’s slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The furnishing of the attached slide presentation is not an admission as to the materiality of any information contain…

Director — William (Chip) Clark: Mr. William (Chip) Clark was elected as a Class I director of Aldeyra Therapeutics, Inc.

Other Events. On April 3, 2025, Aldeyra issued the Press Release to announce that it had received a Complete Response Letter (“2025 Complete Response Letter”) from the U.S. Food & Drug Administration (“FDA”) regarding the Company’s resubmitted New Drug Application (“resubmitted NDA”) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. In the 2025 Complete Response Letter, the FDA stated that the NDA “failed to demonstrate efficacy in adequate and well cont…

Entry into a Material Definitive Agreement. On November 15, 2024, Aldeyra Therapeutics, Inc. (the “Company”) entered into the Extension Side Letter (the “Extension Letter”) with AbbVie Inc. (“AbbVie”), which amended certain terms of the Exclusive Option Agreement (the “Option Agreement”) between the Company and AbbVie, dated October 31, 2023. The Extension Letter makes certain changes to the Option Agreement, among other things, providing that the Company will conduct certain launch activitie…

Principal Financial Officer and Principal Accounting Officer — Michael Alfieri: Appointment of Michael Alfieri as the Company’s principal financial officer and principal accounting officer.

Entry into a Material Definitive Agreement. Open Market Sale Agreement SM As previously reported, on March 11, 2021, Aldeyra Therapeutics, Inc. (the “Company”) entered into a sale agreement with Jefferies LLC (“Agent”) to sell shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), from time to time through the Agent, acting as sales agent, having a maximum aggregate offering price of $100,000,000 (the “Prior Sales Agreement”). The issuances and sales under the…

Regulation FD Disclosure. On April 25, 2024, Aldeyra Therapeutics, Inc. (“Aldeyra”) intends to make a slide presentation at its 2024 Research & Development Day (the “2024 Research and Development Day”) in person in New York City and by webcast on Aldeyra’s website. A copy of Aldeyra’s slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The furnishing of the attached slide presentation is not an admission as to the materia…

Other Events. On November 27, 2023, Aldeyra issued the Press Release to announce that it had received a Complete Response Letter (“Complete Response Letter”) from the U.S. Food & Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. In the Complete Response Letter, the FDA stated that the NDA did not demonstrate “efficacy in treating ocular symptoms associated with dry eyes” and…

Entry into a Material Definitive Agreement On October 31, 2023 (the “Effective Date”), Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) entered into an exclusive option agreement (the “Option Agreement”) with AbbVie Inc. (“AbbVie”), pursuant to which Aldeyra granted AbbVie an exclusive option (the “Option”) to obtain (a) a co-exclusive license in the United States to facilitate a collaboration with Aldeyra to develop, manufacture and commercialize reproxalap in the United States, (b) a…

Other Events On October 16, 2023, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that it received minutes from a late-cycle review meeting (the “Minutes”) with the U.S. Food and Drug Administration (the “FDA”) relating to the new drug application (“NDA”) for reproxalap for the treatment of the signs and symptoms of dry eye disease. The Minutes identified substantive review issues in connection with the NDA for reproxalap. The FDA stated that “[i]t does not appear that you h…

Other Events. On June 21, 2023, Aldeyra Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) to announce that, based on U.S. Food & Drug Administration (FDA) determination of lack of adequate and well controlled investigations in the scientific literature, the Company received a Complete Response Letter from the FDA for the 505(b)(2) New Drug Application of ADX-2191 (methotrexate for injection, USP) for the treatment of primary vitreoretinal lymphoma. The Press Rele…